| Name | Title | Contact Details |
|---|---|---|
Abhinav Shukla |
Chief Technical Officer | Profile |
Cellarity`s mission is to fundamentally transform the way medicines are created through the development of the first full stack digital cell. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single cell technologies, and machine learning to encode biology, model interventions, and purposefully design breakthrough medicines. By focusing on the cellular changes that underlie disease instead of a single target, Cellarity`s approach uncovers new biology and treatments and is applicable to a vast array of disease areas. The company currently has programs underway in metabolic disease, hematology, immuno-oncology, and respiratory disease. The company has raised $123 million as part of a Series B funding round with contributions from funds and accounts managed by Blackrock, The Baupost Group, Banque Pictet on behalf of their clients, and eight other investors alongside Flagship Pioneering.
Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.
C16 was founded with the objective of creating a sustainable, environmentally friendly alternative to conflict palm oil. By offering producers, refiners, traders and consumers of palm oil an opportunity to invest part of their production into bio-based oils and sustainability efforts, our aim is to reduce the environmental footprint of palm oil production and protect precious natural land, wildlife and resources in the process.
Molecular Therapeutics, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hawaii Bioenergy is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.